August 4, 2025Oncology ReviewsOpen Access

Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach

View Full Paper

Ask AI

Bookmark

Triplet therapy significantly improves overall survival in metastatic hormone-sensitive prostate cancer patients compared to standard treatments.
Evidence revealed that abiraterone or darolutamide-containing regimens offer better outcomes, especially for high-volume disease.
Analysis included 52 studies, featuring randomized controlled trials and meta-analyses to assess therapy effectiveness.
Darolutamide-based triplet therapy may also benefit patients with varying risk levels when tailored appropriately.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Critical review assessing triplet therapy's effectiveness in improving survival in patients with metastatic hormone-sensitive prostate cancer, suggesting tailored treatment.

Cite This Study

Zapatero et al. (2025) studied this question.

synapsesocial.com/papers/689a0f8de6551bb0af8d0e56 https://doi.org/10.3389/or.2025.1599292

View Full Paper

Ask AI

Bookmark

Implication

Critical review assessing triplet therapy's effectiveness in improving survival in patients with metastatic hormone-sensitive prostate cancer, suggesting tailored treatment.

Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach

Key Points

Discussion

Implication

Cite This Study

Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider